

Track record – Services – Strategic market access

Determinants of Increasing the Likelihood for a Positive Drug Reimbursement

Recommendation in Scotland. Pantiri K, Baeten S, Majer I, Heeg B, Charokopou M. HC1 –Value in Health 11/2014; 17(7):A325.

Comparison of factors influencing reimbursement and coverage decisions in Scotland (SMC), the Netherlands (NZI) and Germany (G-BA) Charokopou M, Alleman CJ, Verleger K, Spoorendonk JA, Schmidt R, Schoeman O, Heeg B Value in Health 11/2014; 17(7):A325.

Factors influencing dutch drug reimbursement recommendations; a database analysis. Alleman CJ, Spoorendonk JA, Charokopou M, Hensen M, Heeg B Value in health 2014

Comparison of Coverage and Reimbursement Decisions in Germany (AMNOG) and Scotland (SMC). Charokopou M, Heeg B, Schoeman O, Müller S, Tempest M.J, Schlagmuller S.C, Wilke T. A Value in Health. 2013;16(7):A475–A476.

The Impact of AMNOG on Drug Reimbursement in Germany. Heeg B, Schoeman O, Müller S, Wilke T. Value in Health. 2013;16(7):A459.

The use and impact of value of information analysis in decision-making. Chuang L H, Treur M, Heeg B, Van Hout B, Filonenko A .A30. Value in Health 05/2013; 16(3):

Factors Influencing Drug Reimbursement Decision in Scotland. Charokopou M., Heeg B., Majer I.M.. RE1 Value in Health 11/2012; 15(7):A287.

Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ. Clin Ther. 2010 Aug;32(9):1651-61. doi: 10.1016/j.clinthera.2010.08.006.

Criteria for inclusion of vaccinations in public programmes. Houweling H, Verweij M, Ruitenber EJ; National Immunisation Programme Review Committee of the Health Council of the Netherlands. Vaccine. 2010 Apr 9;28(17):2924-31. doi: 10.1016/j.vaccine.2010.02.021. Epub 2010 Feb 26. Review.

Which factors are important in adults' uptake of a (pre)pandemic influenza vaccine? Zijtregtop EA, Wilschut J, Koelma N, Van Delden JJ, Stolk RP, Van Steenberg J, Broer J, Wolters B, Postma MJ, Hak E. Vaccine. 2009 Dec 10;28(1):207-27. doi: 10.1016/j.vaccine.2009.09.099. Epub 2009 Oct 2.

Comparing forecasted with actual budget impact: reimbursed cancer drugs in the Netherlands. Thuresson B, Heeg B, Botteman M. PCN32. Value in Health 01/2010; 13(7).

[Dutch Institute for Health Care Improvement revised guideline, 'Sexually transmitted diseases and neonatal herpes']. Bleker OP, van der Meijden WI, Wittenberg J, van Bergen JE, Boeke AJ, van Doornum GJ, Henquet CJ, Galama JM, Postma MJ, Prins JM, van Voorst Vader PC; Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing. Ned Tijdschr Geneeskd. 2003 Apr 12;147(15):695-9. Dutch.

[Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations]. Postma MJ, Kwik JJ, Rutten WJ, de Jong-van den Berg LT, Brouwers JR. Ned Tijdschr Geneeskd. 2002 Jun 8;146(23):1082-7. Dutch.